NRX Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
NRX Pharmaceuticals, Inc. (NRXP) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.81M.
- NRX Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$420.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$451.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$227.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$865.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$503.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$3.04M, a 581.01% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $632.00K, a 86.86% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.39M 10-Q · filed 2026-08-14 | $941.00K derived: sum of 3 quarters · filed 2026-08-14 | $714.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$420.00K 10-Q · filed 2026-05-15 | -$871.00K derived: sum of 2 quarters · filed 2026-05-15 | -$1.10M derived: sum of 3 quarters · filed 2026-05-15 | -$1.13M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | -$451.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$678.00K derived: sum of 2 quarters · filed 2026-03-23 | -$706.00K derived: sum of 3 quarters · filed 2026-08-14 | -$865.00K 10-K · filed 2026-03-23 | |||
| 2025-09-30 | -$227.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$255.00K derived: sum of 2 quarters · filed 2026-08-14 | -$414.00K 10-Q · filed 2025-11-14 | -$1.02M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | -$28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$187.00K 10-Q · filed 2026-08-14 | -$790.00K derived: sum of 3 quarters · filed 2026-08-14 | -$1.34M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | -$159.00K 10-Q · filed 2026-05-15 | -$762.00K derived: sum of 2 quarters · filed 2026-05-15 | -$1.31M derived: sum of 3 quarters · filed 2026-05-15 | -$412.00K derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | -$603.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$1.15M derived: sum of 2 quarters · filed 2026-03-23 | -$253.00K derived: sum of 3 quarters · filed 2026-03-23 | -$503.00K 10-K · filed 2026-03-23 | |||
| 2024-09-30 | -$548.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $350.00K derived: sum of 2 quarters · filed 2025-11-14 | $100.00K 10-Q · filed 2025-11-14 | -$1.39M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $898.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $648.00K 10-Q · filed 2025-08-18 | -$838.00K derived: sum of 3 quarters · filed 2025-08-18 | -$1.47M derived: sum of 4 quarters · filed 2025-08-18 | |||
| 2024-03-31 | -$250.00K 10-Q · filed 2025-05-15 | -$1.74M derived: sum of 2 quarters · filed 2025-05-15 | -$2.37M derived: sum of 3 quarters · filed 2025-05-15 | -$2.80M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$2.12M derived: sum of 2 quarters · filed 2025-03-14 | -$2.55M derived: sum of 3 quarters · filed 2025-03-14 | -$3.04M 10-K · filed 2025-03-14 | |||
| 2023-09-30 | -$632.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.06M derived: sum of 2 quarters · filed 2024-11-14 | -$1.55M 10-Q · filed 2024-11-14 | -$2.37M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | -$431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$922.00K 10-Q · filed 2024-08-14 | -$1.73M derived: sum of 3 quarters · filed 2024-08-14 | -$3.05M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | -$491.00K 10-Q · filed 2024-05-14 | -$1.30M derived: sum of 2 quarters · filed 2024-05-14 | -$2.62M derived: sum of 3 quarters · filed 2024-05-14 | $1.87M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$811.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$2.13M derived: sum of 2 quarters · filed 2024-03-29 | $2.36M derived: sum of 3 quarters · filed 2024-03-29 | $632.00K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.17M derived: sum of 2 quarters · filed 2023-11-14 | $1.44M 10-Q · filed 2023-11-14 | $202.00K derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $4.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $2.76M 10-Q · filed 2023-08-14 | $1.52M derived: sum of 3 quarters · filed 2023-08-14 | $2.72M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$1.73M 10-Q · filed 2023-05-15 | -$2.97M derived: sum of 2 quarters · filed 2023-05-15 | -$1.77M derived: sum of 3 quarters · filed 2023-05-15 | $3.03M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$40.00K derived: sum of 2 quarters · filed 2023-03-31 | $4.76M derived: sum of 3 quarters · filed 2023-03-31 | $4.81M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.00M derived: sum of 2 quarters · filed 2022-11-14 | $6.05M 10-Q · filed 2022-11-14 | $6.05M 10-Q · filed 2021-11-15 | $5.73M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $4.85M 10-Q · filed 2022-08-15 | $4.85M 10-Q · filed 2021-08-16 | $4.53M derived: sum of 3 quarters · filed 2022-08-15 | $4.95M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $50.00K 10-Q · filed 2022-05-16 | -$267.59K derived: sum of 2 quarters · filed 2022-05-16 | $146.24K derived: sum of 3 quarters · filed 2022-08-12 | $193.00K derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-12-31 | -$317.59K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $96.24K derived: sum of 2 quarters · filed 2022-08-12 | $143.00K derived: sum of 3 quarters · filed 2022-08-12 | $143.00K 10-K · filed 2022-03-31 | $30.35K 10-K · filed 2021-04-01 | ||
| 2020-09-30 | $413.83K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $460.59K derived: sum of 2 quarters · filed 2022-08-12 | $460.59K 10-Q/A · filed 2022-08-12 | $10.80K 10-Q · filed 2020-11-16 | $446.84K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-06-30 | $46.76K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-08-12 | $46.76K 10-Q/A · filed 2022-08-12 | $33.20K 10-Q · filed 2020-08-14 | $33.01K derived: sum of 3 quarters · filed 2022-08-12 | $6.88K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | -$13.75K derived: sum of 2 quarters · filed 2021-05-14 | -$39.88K derived: sum of 3 quarters · filed 2021-05-14 | -$48.90K derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | -$13.75K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | -$39.88K derived: sum of 2 quarters · filed 2021-05-14 | -$48.90K derived: sum of 3 quarters · filed 2021-05-14 | -$19.11K 10-K/A · filed 2021-05-14 | |||
| 2019-09-30 | -$26.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$35.15K derived: sum of 2 quarters · filed 2020-11-16 | -$5.36K 10-Q · filed 2020-11-16 | -$32.98K derived: sum of 4 quarters · filed 2020-11-16 | |||
| 2019-06-30 | -$9.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $20.77K 10-Q · filed 2020-08-14 | -$6.85K derived: sum of 3 quarters · filed 2020-08-14 | -$36.55K derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | $29.78K 10-Q · filed 2020-05-15 | $2.17K derived: sum of 2 quarters · filed 2020-05-15 | -$27.54K derived: sum of 3 quarters · filed 2020-05-15 | -$18.88K derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | -$27.62K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$57.32K derived: sum of 2 quarters · filed 2020-03-30 | -$48.66K derived: sum of 3 quarters · filed 2020-03-30 | -$67.89K 10-K · filed 2020-03-30 | |||
| 2018-09-30 | -$29.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$21.05K derived: sum of 2 quarters · filed 2019-11-14 | -$40.27K 10-Q · filed 2019-11-14 | $0.00 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $8.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$10.57K 10-Q · filed 2019-08-14 | $76.43K derived: sum of 3 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | -$19.22K 10-Q · filed 2019-05-15 | $67.78K derived: sum of 2 quarters · filed 2019-05-15 | |||||
| 2017-12-31 | $87.00K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |